Jason Gotlib, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gotlib’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$74,439
Medicare paid this office $74,439 for 273 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $23,587 | $106 |
| Return visit (30+ min) | 119 | $19,723 | $83 |
| Return visit (30+ min) | 96 | $18,103 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,656 | $155 |
| New patient visit (60+ min) | 26 | $4,153 | $160 |
See all 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $23,587 | $106 |
| Return visit (30+ min) | 119 | $19,723 | $83 |
| Return visit (30+ min) | 96 | $18,103 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,656 | $155 |
| New patient visit (60+ min) | 26 | $4,153 | $160 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,772 | $74 |
Who their Medicare patients are
273 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 14% · Women 54% · Also on Medicaid 15% · Health risk score 2.05. At or below the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 64% · Chronic kidney disease 31% · Coronary heart disease 29% · Atrial fibrillation 24% · Cancer 21% · Heart failure 19% · Diabetes 17% · COPD 14% · Depression 14% · Stroke 10% · Dementia 9%.
The office billed $293,029, Medicare allowed $96,356 and paid $74,439; for 712 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 273 | 712 | 75 | 2.05 | $293,029 | $74,439 |
| 2023 | 277 | 738 | 74 | 1.90 | $277,731 | $74,067 |
| 2022 | 281 | 804 | 73 | 2.11 | $344,713 | $74,945 |
| 2021 | 261 | 796 | 73 | 2.24 | $366,809 | $77,427 |
| 2020 | 250 | 829 | 73 | 2.44 | $341,806 | $72,982 |
| 2019 | 238 | 681 | 72 | 2.15 | $150,249 | $58,571 |
| 2018 | 206 | 680 | 73 | 2.34 | $145,109 | $57,326 |
| 2017 | 208 | 728 | 71 | 2.55 | $195,047 | $62,832 |
| 2016 | 196 | 664 | 72 | 2.15 | $176,448 | $54,600 |
| 2015 | 148 | 455 | 74 | 2.19 | $126,815 | $38,899 |
| 2014 | 239 | 761 | 73 | 2.32 | $192,185 | $59,971 |
| 2013 | 251 | 834 | 71 | 2.09 | $227,350 | $67,830 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 181 | $32,307 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $28,508 | $109 |
| New patient visit (60+ min) | 36 | $5,678 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,318 | $160 |
| Hospital discharge day management, 30 minutes or less | 28 | $2,225 | $74 |
2022: 5 services
| Return visit (30+ min) | 191 | $34,662 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $26,289 | $92 |
| New patient visit (60+ min) | 29 | $4,892 | $169 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,879 | $181 |
| Hospital discharge day management, 30 minutes or less | 32 | $2,476 | $67 |
2021: 5 services
| Return visit (30+ min) | 167 | $37,467 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $22,719 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $7,032 | $185 |
| New patient visit (60+ min) | 35 | $5,852 | $167 |
| Hospital discharge day management, 30 minutes or less | 30 | $2,445 | $68 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $28,069 | $97 |
| Return visit (30+ min) | 145 | $23,316 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $8,922 | $190 |
| New patient visit (60+ min) | 33 | $4,767 | $144 |
| Hospital discharge day management, 30 minutes or less | 41 | $3,085 | $70 |
| Return visit (30+ min) | 37 | $2,962 | $72 |
2019: 5 services
| Return visit (30+ min) | 138 | $24,156 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $17,262 | $94 |
| New patient visit (60+ min) | 52 | $7,484 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,607 | $184 |
| Hospital discharge day management, 30 minutes or less | 30 | $2,229 | $66 |
2018: 5 services
| Return visit (30+ min) | 125 | $25,130 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $17,132 | $94 |
| New patient visit (60+ min) | 40 | $5,829 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,458 | $182 |
| Hospital discharge day management, 30 minutes or less | 21 | $1,672 | $67 |
2017: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $25,800 | $93 |
| Return visit (30+ min) | 121 | $23,045 | $68 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,257 | $181 |
| New patient visit (60+ min) | 35 | $5,118 | $146 |
| Hospital discharge day management, 30 minutes or less | 25 | $1,789 | $66 |
2016: 5 services
| Return visit (30+ min) | 128 | $25,455 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $17,774 | $91 |
| New patient visit (60+ min) | 44 | $6,488 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,245 | $180 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,052 | $66 |
2015: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $19,744 | $92 |
| Return visit (30+ min) | 96 | $13,216 | $70 |
| New patient visit (60+ min) | 11 | $1,653 | $150 |
| Hospital discharge day management, 30 minutes or less | 13 | $841 | $60 |
2014: 5 services
| Return visit (30+ min) | 157 | $29,900 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 37 | $17,114 | $90 |
| New patient visit (60+ min) | 40 | $5,736 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,333 | $175 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,088 | $64 |
2013: 5 services
| Return visit (30+ min) | 145 | $26,841 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $23,600 | $90 |
| New patient visit (60+ min) | 56 | $7,460 | $133 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,853 | $176 |
| Hospital discharge day management, 30 minutes or less | 27 | $1,856 | $64 |
Medicaid work
$3,557 in 2023
Medicaid paid $3,557 for 57 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 57 | $3,557 |
| 2023 | 57 | 1 | 12 | $3,557 |
| 2022 | 98 | 1 | 18 | $4,016 |
| 2021 | 65 | 1 | 14 | $4,700 |
See the largest Medicaid services in earlier years
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 98 | $4,016 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 65 | $4,700 |
Drugs they prescribed that Part D paid
$749,988
Pharmacies billed $749,988 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
38 generic and 42 brand-name prescriptions · $749,988 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ayvakit | 15 | $592,340 | $39,489 |
Year by year
| 2024 | 80 | 21 | None | 53% | $749,988 |
| 2023 | 36 | 16 | 0% (0) | None | $48,701 |
| 2022 | 61 | 23 | 0% (0) | 43% | $274,851 |
| 2021 | 92 | 29 | 0% (0) | 46% | $657,921 |
| 2020 | 186 | 47 | None | 43% | $793,558 |
| 2019 | 267 | 75 | 0% (0) | 43% | $1,091,804 |
| 2018 | 263 | 61 | 0% (0) | 54% | $1,422,005 |
| 2017 | 289 | 67 | 0% (0) | 39% | $1,060,538 |
| 2016 | 214 | 51 | None | 49% | $958,550 |
| 2015 | 246 | 51 | 0% (0) | 53% | $939,232 |
| 2014 | 524 | 74 | None | 51% | $2,315,588 |
| 2013 | 519 | 76 | None | None | $1,705,935 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Panzyga | Immune globulin | 13 | $76,512 | $5,886 |
2021: 2 drugs
| Jakafi | 35 | $573,992 | $16,400 |
| Allopurinol | 13 | $80 | $6 |
2020: 3 drugs
| Jakafi | 53 | $649,968 | $12,264 |
| Acyclovir | 18 | $254 | $14 |
| Sulfamethoxazole-Trimethoprim | 11 | $75 | $7 |
2019: 7 drugs
| Jakafi | 47 | $625,516 | $13,309 |
| Procrit | 12 | $51,325 | $4,277 |
| Hydroxyurea | 16 | $816 | $51 |
| Allopurinol | 34 | $420 | $12 |
| Valacyclovir | 11 | $303 | $28 |
| Acyclovir | 14 | $133 | $10 |
| Prednisone | 14 | $106 | $8 |
2018: 4 drugs
| Jakafi | 67 | $885,604 | $13,218 |
| Hydroxyurea | 24 | $1,022 | $43 |
| Allopurinol | 18 | $278 | $15 |
| Acyclovir | 14 | $133 | $9 |
2017: 6 drugs
| Jakafi | 68 | $730,970 | $10,750 |
| Revlimid | 12 | $104,342 | $8,695 |
| Hydroxyurea | 30 | $1,950 | $65 |
| Allopurinol | 27 | $394 | $15 |
| Ondansetron | 13 | $283 | $22 |
| Acyclovir | 15 | $213 | $14 |
2016: 3 drugs
| Jakafi | 80 | $854,886 | $10,686 |
| Hydroxyurea | 23 | $744 | $32 |
| Allopurinol | 22 | $233 | $11 |
2015: 6 drugs
| Jakafi | 82 | $790,950 | $9,646 |
| Procrit | 12 | $43,216 | $3,601 |
| Hydroxyurea | 28 | $1,125 | $40 |
| Ondansetron | 17 | $874 | $51 |
| Allopurinol | 21 | $243 | $12 |
| Ranitidine | 13 | $221 | $17 |
2014: 9 drugs
| Jakafi | 141 | $1,502,474 | $10,656 |
| Revlimid | 43 | $309,543 | $7,199 |
| Exjade | 19 | $179,255 | $9,434 |
| Procrit | 21 | $52,904 | $2,519 |
| Hydroxyurea | 83 | $3,048 | $37 |
| Anagrelide | 19 | $383 | $20 |
| Allopurinol | 48 | $337 | $7 |
| Ranitidine | 14 | $314 | $22 |
| Prednisone | 15 | $149 | $10 |
2013: 13 drugs
| Jakafi | 116 | $1,037,198 | $8,941 |
| Revlimid | 42 | $338,722 | $8,065 |
| Exjade | 30 | $206,904 | $6,897 |
| Sprycel | 11 | $48,779 | $4,434 |
| Procrit | 13 | $30,205 | $2,323 |
| Hydroxyurea | 55 | $2,514 | $46 |
| Pantoprazole | 22 | $301 | $14 |
| Anagrelide | 11 | $247 | $22 |
| Allopurinol | 34 | $226 | $7 |
| Acyclovir | 14 | $212 | $15 |
| Ranitidine | 15 | $186 | $12 |
| Gabapentin | 17 | $98 | $6 |
| Dexamethasone | 16 | $85 | $5 |
Money from drug and device companies
$19,362 in 2025
| 2025 | 3 | 7 | $19,142 | $19,362 |
| 2024 | 2 | 6 | $1,999 | $2,285 |
| 2023 | 1 | 5 | $9,685 | $9,797 |
| 2022 | 3 | 7 | $7,163 | $7,509 |
| 2021 | 3 | 7 | $13,014 | $13,105 |
| 2020 | 1 | 3 | $7,855 | $7,855 |
| 2019 | 1 | 3 | $3,075 | $3,137 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Blueprint Medicines | None | $10,129 | 2 payments
|
| Incyte | None | $9,212 | 4 payments
|
| Celgene | Reblozyl | $21 | 1 payment
|
See all 7 published payments
| Celgene | Meals · 2025-10-02 | Reblozyl | $21 |
| Incyte | Consulting · 2025-07-12 | None | $923 |
| Blueprint Medicines | Meals · 2025-06-14 | None | $130 |
| Incyte | Meals · 2025-06-12 | None | $69 |
| Incyte | Consulting · 2025-01-28 | None | $4,110 |
| Incyte | Consulting · 2025-01-28 | None | $4,110 |
| Blueprint Medicines | Paid to speak or teach · 2025-01-02 | None | $9,999 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,285
| Incyte | None | $2,215 | 5 payments
|
| Blueprint Medicines | Ayvakit | $70 | 1 payment
|
2023: $9,797
| Incyte | Pemazyre | $9,797 | 5 payments
|
2022: $7,509
| Incyte | Pemazyre | $5,356 | 2 payments
|
| Blueprint Medicines | None | $1,886 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | None | $267 | 1 payment
|
2021: $13,105
| Blueprint Medicines | Ayvakit | $8,005 | 5 payments
|
| Incyte | Pemazyre | $3,075 | 1 payment
|
| AbbVie | None | $2,025 | 1 payment
|
2020: $7,855
| Blueprint Medicines | Ayvakit | $7,855 | 3 payments
|
2019: $3,137
| Incyte | None | $3,137 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2021 | Their institution | $779,811 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2020 | Their institution | $618,728 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2021 | Their institution | $591,278 |
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2020 | Their institution | $525,788 |
| Incyte Corporation · A Study To Evaluate the Safety, Tolerability of Incb160058 in Participants With Myeloproliferative Neoplasms · 2025 | Their institution | $447,905 |
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2022 | Their institution | $408,660 |
| Blueprint Medicines Corporation · 2020 | Their institution | $366,018 |
| Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2021 | Their institution | $320,851 |
| Incyte Corporation · A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of Incagn01876 in Subjects With Advanced Or Metastatic Solid Tumors · 2020 | Their institution | $315,633 |
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2023 | Their institution | $303,403 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2022 | Their institution | $285,852 |
| Blueprint Medicines Corporation · 2022-Rfp-002: Characterizing the Cellular Dynamics of Kit D816v Mutated Systemic Mastocytosis on Avapritinib and Blu-263 · 2024 | Their institution | $193,230 |
| Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Incb161734 in Participants With Advanced Or Metastatic Solid Tumors With Kras G12d Mutation · 2024 | Their institution | $191,967 |
| Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence (Ace-536-Mf-001) · 2019 | Their institution | $146,545 |
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2024 | Their institution | $145,304 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2023 | Their institution | $142,488 |
| Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2022 | Their institution | $116,624 |
| Blueprint Medicines Corporation · 2022-Rfp-002: Characterizing the Cellular Dynamics of Kit D816v Mutated Systemic Mastocytosis on Avapritinib and Blu-263 · 2023 | Their institution | $115,937 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2021 | Their institution | $111,441 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2024 | Their institution | $101,355 |
| Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2022 | Their institution | $97,928 |
| Blueprint Medicines Corporation · Blu-285-2202 / Blu-285-2203 / Blu-263-1201 · 2022 | Their institution | $96,000 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2022 | Their institution | $94,655 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2024 | Their institution | $86,008 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2023 | Their institution | $81,874 |
| Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2021 | Their institution | $80,750 |
| Blueprint Medicines Corporation · (Explorer) Study of Blu-285 in Patients With Advanced Systemic Mastocytosis (Advsm) and Relapsed Or Refractory Myeloid Malignancies · 2023 | Their institution | $80,219 |
| Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2023 | Their institution | $74,904 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2023 | Their institution | $72,102 |
| SANOFI US SERVICES INC. · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2025 | Their institution | $70,975 |
| Blueprint Medicines Corporation · A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study To Evaluate Safety and Efficacy of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy · 2025 | Their institution | $69,980 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2022 | Their institution | $65,423 |
| Blueprint Medicines Corporation · An Open-Label, Single Arm, Phase 2 Study To Evaluate Efficacy and Safety of Avapritinib (Blu-285), A Selective Kit Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis · 2025 | Their institution | $63,617 |
| Incyte Corporation · This Study Is Being Conducted To Assess the Safety, Tolerability, and Pharmacokinetics of Incb160058 in Participants With Myeloproliferative Neoplasms. · 2025 | Their institution | $62,214 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2025 | Their institution | $59,059 |
| Acerta Pharma LLC · A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acp-196 in Combination With Obinutuzumab, and Acp-196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2024 | Their institution | $58,000 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021 | Their institution | $44,285 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2025 | Their institution | $42,890 |
| Seattle Genetics, Inc. · A Pilot Study of Brentuximab Vedotin Sgn-35 in Cd30-Positive Systemic Mastocytosis With Or Without An Associated Hematological Clonal Non-Mast Cell Lineage Disease Ahnmd · 2019 | Their institution | $42,116 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2020 | Their institution | $41,015 |
| SANOFI US SERVICES INC. · A Phase 1/2, Open-Label, 2-Arm Study Evaluating Blu-263 As Monotherapy and in Combination With Azacitidine, in Patients With Kit Altered Hematologic Malignancies · 2025 | Their institution | $38,464 |
| Acerta Pharma LLC · A Randomized,Multicenter,Open Label,3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil,Acp 196 in Combination With Obinutuzumaband Acp 196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2025 | Their institution | $38,185 |
| Incyte Corporation · This Phase 1/2, Open-Label, Dose-Finding Study Is Intended To Evaluate the Safety and Tolerability, Pk, Pd, and Efficacy of Incb000928 Administered As Monotherapy Or in Combination With Ruxolitinib in Participants With Mf Who Are Transfusion-Dependent Or Presenting With Symptomatic Anemia. This Study Will Consist of 2 Parts: Dose Escalation and Expansion. · 2025 | Their institution | $36,686 |
| Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence · 2020 | Their institution | $36,036 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2021 | Their institution | $33,979 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloid/Lymphoid Neoplasms With Fgfr1 Rearrangement · 2024 | Their institution | $33,776 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Active-Controlled Study Evaluating Momelotinib Vs. Ruxolitinib in Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post- Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2019 | Their institution | $23,548 |
| Gilead Sciences, Inc. · Open-Label Study To Assess the Long-Term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera Or Essential Thrombocythemia · 2019 | Their institution | $23,390 |
| Pharmacyclics LLC, an AbbVie Company · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2023 | Their institution | $21,371 |
| Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind Active-Controlled Study Evaluating Momelotinib Vs. Ruxolitinib in Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post- Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2020 | Their institution | $21,246 |
| ABBVIE INC. · A Phase 2 Open-Label Study of the Efficacy and Safety of Abt-199 (Gdc-0199) in Chronic Lymphocytic Leukemia (Cll) Subjects With Relapse Or Refractory To B-Cell Receptor Signaling Pathway Inhibitor Therapy · 2022 | Their institution | $20,992 |
| Pharmacyclics LLC, an AbbVie Company · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2022 | Their institution | $15,518 |
| Gilead Sciences, Inc. · Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (Pmf) Or Post-Polycythemia Vera Or Post-Essential Thrombocythemia Myelofibrosis (Post-Pv/Et Mf) · 2019 | Their institution | $13,144 |
| Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2022 | Their institution | $11,888 |
| ABBVIE INC. · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2024 | Their institution | $10,700 |
| Incyte Corporation · A Phase 2, Open Label, Single Arm, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Advanced/Metastatic Or Surgically Unresectable Cholangiocarcinoma Including Fgfr2 Translocations Who Failed Previous Therapy · 2020 | Their institution | $10,560 |
| ABBVIE INC. · A Phase 2 Open-Label Study of the Efficacy and Safety of Abt-199 (Gdc-0199) in Chronic Lymphocytic Leukemia (Cll) Subjects With Relapse Or Refractory To B-Cell Receptor Signaling Pathway Inhibitor Therapy · 2023 | Their institution | $8,909 |
| Incyte Corporation · Prospective, Longitudinal, Non Interventional Study of Disease Burden and Treatment of Patients With Low Risk Myelofibrosis Mf Or High Risk Essential Thrombocythemia Et Or Et Patients Receiving Et Directed Therapy · 2019 | Their institution | $8,144 |
| ABBVIE INC. · Extended Treatment Protocol for Subjects Continuing To Benefit From Ibrutinib. · 2025 | Their institution | $7,613 |
| Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety O - A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence · 2022 | Their institution | $6,805 |
| Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety O · 2021 | Their institution | $6,215 |
| F. Hoffmann-La Roche AG · Safety and Efficacy of Zinpentraxin Alfa As Monotherapy Or in Combination With Ruxolitinib in Myelofibrosis: Stage 1 of A Phase II Trial · 2023 | This clinician | $4,557 |
| Novartis Pharmaceuticals Corporation · Research Related Publications Support · 2020 | This clinician | $3,750 |
| Incyte Corporation · A Phase 2, Open Label, Monotherapy, Multicenter Study To Evaluate the Efficacy and Safety of Incb054828 in Subjects With Myeloidlymphoid Neoplasms With Fgfr1 Rearrangement · 2019 | Their institution | $3,226 |
| Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2023 | Their institution | $2,240 |
| Blueprint Medicines Corporation · An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis · 2024 | Their institution | $2,240 |
| Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022 | Their institution | $1,728 |
| Incyte Corporation · A Phase 1/2 Open-Label, Multicenter Study of Incb000928 Administered As A Monotherapy Or in Combination With Ruxolitinib in Participants With Anemia Due To Myeloproliferative Disorders · 2020 | Their institution | $1,611 |
| Incyte Corporation · Ruxolitinib in Primary Eosinophilic Disorders and Idiopathic Hypereosinophilic Syndrome · 2022 | Their institution | $1,250 |
| Novartis Pharmaceuticals Corporation · A Single Arm Phase II Open Label Study To Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered To Patients With Aggressive Systemic Mastocytosis Or Mast Cell Leukemia Plus Or Minus An Associated Hematological Clonal Non Mast · 2019 | Their institution | $1,178 |
| Celgene Corporation · A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With Or Without Red Blood Cell-Transfusion Dependence (Ace-536-Mf-001) · 2019 | This clinician | $935 |
| Acerta Pharma LLC · A Randomized,Multicenter,Open Label,3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil,Acp 196 in Combination With Obinutuzumaband Acp 196 Monotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia · 2024 | Their institution | $448 |
| Gilead Sciences, Inc. · A Phase 1b Open-Label Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib As Therapy for Primary, Post-Polycythemia Vera, Or Post-Essential Thrombocythemia Myelofibrosis With Progressive Or Relapsed Disease · 2020 | Their institution | $391 |
| Incyte Corporation · A Phase 1, Open-Label, Multicenter Study of Inca033989 in Participants With Myeloproliferative Neoplasms · 2023 | Their institution | $107 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790827640
- Licence
- CA A060833
- Trained
- Stanford University School of Medicine, 1995
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X)
- Mailing address
- 875 Blake Wilbur Drive, Room 2327b, Stanford, CA, 94305
- NPI first listed
- 2007-02-13
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.